NASDAQ:AKRO Akero Therapeutics (AKRO) Stock Price, News & Analysis $26.41 +0.06 (+0.23%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$25.67▼$26.9650-Day Range$21.45▼$28.3252-Week Range$11.25▼$53.77Volume446,533 shsAverage Volume957,008 shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/APrice Target$41.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Akero Therapeutics alerts: Email Address Akero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside55.7% Upside$41.13 Price TargetShort InterestBearish10.40% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.29Based on 2 Articles This WeekInsider TradingSelling Shares$7.79 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.64) to ($4.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.02 out of 5 starsMedical Sector305th out of 910 stocksPharmaceutical Preparations Industry128th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAkero Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Akero Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.40% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Akero Therapeutics has recently increased by 3.75%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 1.3 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Akero Therapeutics this week, compared to 6 articles on an average week.MarketBeat FollowsOnly 1 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,787,723.00 in company stock.Percentage Held by InsidersOnly 7.94% of the stock of Akero Therapeutics is held by insiders.Read more about Akero Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.64) to ($4.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Akero Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Akero Therapeutics Stock (NASDAQ:AKRO)Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More AKRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKRO Stock News HeadlinesAugust 30, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 75,159 SharesAugust 29, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $143,052.00 in StockSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 5 at 9:44 AM | msn.comAkero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right NowSeptember 1, 2024 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $2,045,076.39 in StockAugust 31, 2024 | americanbankingnews.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $143,052.00 in StockAugust 29, 2024 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 8,851 Shares of StockAugust 28, 2024 | globenewswire.comAkero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 28, 2024 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives $41.13 Average PT from AnalystsAugust 28, 2024 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 27, 2024 | businesswire.comAKERO THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKROAugust 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)August 12, 2024 | markets.businessinsider.comBuy Rating Affirmed on Akero Therapeutics Amid Promising EFX Trials and Robust Financial OutlookAugust 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Akero Therapeutics Amidst Advancement in Phase III NASH TrialsAugust 10, 2024 | markets.businessinsider.comBuy Rating for Akero Therapeutics Backed by Strong Financials and Promising Trial OutcomesAugust 9, 2024 | finanznachrichten.deAkero Therapeutics Inc.: Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 9, 2024 | globenewswire.comAkero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateSee More Headlines Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$41.13 High Stock Price Target$56.00 Low Stock Price Target$30.00 Potential Upside/Downside+55.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.50% Return on Assets-27.23% Debt Debt-to-Equity Ratio0.04 Current Ratio24.89 Quick Ratio24.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.49 per share Price / Book2.30Miscellaneous Outstanding Shares69,151,000Free Float63,660,000Market Cap$1.83 billion OptionableOptionable Beta-0.26 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Andrew Cheng M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1.04MDr. Jonathan M. Young J.D. (Age 54)Ph.D., Co-Founder, Executive VP, COO & Secretary Comp: $672.35kDr. Timothy Rolph (Age 70)Co-Founder & Chief Scientific Officer Comp: $722.32kMr. William R. White J.D. (Age 51)Executive VP, CFO, Treasurer & Head of Corporate Development Comp: $678.06kMs. Catriona Yale (Age 52)Executive VP & Chief Development Officer Comp: $678.06kMr. Scott A. Gangloff (Age 50)Chief Technical Officer Mr. David West J.D.Vice President of LegalMr. John J. Schembri (Age 62)Vice President & Head of Finance Mr. Patrick Lamy (Age 51)Senior Vice President of Commercial Strategy More ExecutivesKey CompetitorsAlbireo PharmaNASDAQ:ALBOEnanta PharmaceuticalsNASDAQ:ENTACymaBay TherapeuticsNASDAQ:CBAYRevolution MedicinesNASDAQ:RVMDViking TherapeuticsNASDAQ:VKTXView All CompetitorsInsiders & InstitutionsCatriona YaleSold 5,200 sharesTotal: $143,052.00 ($27.51/share)William Richard WhiteSold 75,159 sharesTotal: $2.05 M ($27.21/share)Catriona YaleSold 8,851 sharesTotal: $243,668.03 ($27.53/share)Perceptive Advisors LLCBought 112,426 shares on 8/16/2024Ownership: 2.169%Algert Global LLCSold 24,562 shares on 8/16/2024Ownership: 0.091%View All Insider TransactionsView All Institutional Transactions AKRO Stock Analysis - Frequently Asked Questions How have AKRO shares performed this year? Akero Therapeutics' stock was trading at $23.35 on January 1st, 2024. Since then, AKRO stock has increased by 13.1% and is now trading at $26.41. View the best growth stocks for 2024 here. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.09. When did Akero Therapeutics IPO? Akero Therapeutics (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Akero Therapeutics' major shareholders? Akero Therapeutics' top institutional investors include Perceptive Advisors LLC (2.17%), Long Focus Capital Management LLC (1.04%), Emerald Advisers LLC (0.75%) and Bank of New York Mellon Corp (0.36%). Insiders that own company stock include Skorpios Trust, G Walmsley Graham, Andrew Cheng, Jonathan Young, Timothy Rolph, Seth Loring Harrison, Catriona Yale, William Richard White, Patrick Lamy and Tomas J Heyman. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB) and Alector (ALEC). This page (NASDAQ:AKRO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.